Translating bioactive peptides for COVID-19 therapy.
Eur J Pharmacol
; 890: 173661, 2021 Jan 05.
Article
in English
| MEDLINE | ID: covidwho-1049782
ABSTRACT
COVID-19 (Coronavirus disease 2019) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense RNA virus. This virus has emerged as a threat to global health, social stability, and the global economy. This pandemic continues to cause rampant mortality worldwide with the dire urgency to develop novel therapeutic agents. To meet this task, this article discusses advances in the research and potential application of bioactive peptides for possible mitigation of infection by SARS-CoV-2. Growing insight into the molecular biology of SARS-CoV-2 has revealed potential druggable targets for bioactive peptides. Bioactive peptides with unique amino acid sequences can mitigate such targets including, type II transmembrane serine proteases (TMPRSS2) inhibition, furin cleavage, and renin-angiotensin-aldosterone system (RAAS) members. Based on current evidence and structure-function analysis, multiple bioactive peptides present potency to neutralize the virus. To date, no SARS-CoV-2-explicit drug has been reported, but we here introduce bioactive peptides in the perspective of their potential activity against SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Peptides
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Limits:
Animals
/
Humans
Language:
English
Journal:
Eur J Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
J.ejphar.2020.173661
Similar
MEDLINE
...
LILACS
LIS